{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:47:44Z","timestamp":1793296064034,"version":"4.5.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"European Alliance of Associations for Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100025178","name":"OpenAI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025178","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ard.2026.03.020","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:54:23Z","timestamp":1776383663000},"page":"1039-1054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2304-5933","authenticated-orcid":false,"given":"Victoria","family":"Konzett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faidra","family":"Laskou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Verschueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimme L.","family":"Hyrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savia","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja A.","family":"Stamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette","family":"Primdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan W.","family":"Schoones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.M.","family":"Landew\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kerschbaumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2026.03.020_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.ard.2026.03.020_bib0002","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.berh.2018.10.005","article-title":"Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis","volume":"32","author":"van der Woude","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2026.03.020_bib0003","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","article-title":"Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021","volume":"5","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"13","key":"10.1016\/j.ard.2026.03.020_bib0004","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ard.2026.03.020_bib0005","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2026.03.020_bib0006","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.03.020_bib0009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"10.1016\/j.ard.2026.03.020_bib110","first-page":"00075","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update","volume":"S0003-4967","author":"Smolen","year":"2026","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.03.020_bib0007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ard.2026.03.020_bib0010","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41584-024-01169-7","article-title":"Management strategies in rheumatoid arthritis","volume":"20","author":"Konzett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.ard.2026.03.020_bib0011","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/art.42640","article-title":"Identification, monitoring, and management of rheumatoid arthritis-associated interstitial lung disease","volume":"75","author":"Koduri","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2026.03.020_bib0012","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/annrheumdis-2016-209846","article-title":"EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis","volume":"76","author":"van Steenbergen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2026.03.020_bib0013","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2665-9913(23)00241-2","article-title":"Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials","volume":"5","author":"Rivellese","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2026.03.020_bib0014","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1016\/S2665-9913(24)00021-3","article-title":"Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial","volume":"6","author":"Kjorholt","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.03.020_bib0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.03.020_bib0016","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/ard-2022-223358","article-title":"Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Bergstra","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.03.020_bib108","doi-asserted-by":"crossref","unstructured":"Smolen J.S., Edwards C.J., Konzett V., Laskou F., Aletaha D., Caporali R., et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Ann Rheum Dis 2026 Mar 12:S0003-4967(26)00075. https:\/\/doi.org\/10.1016\/j.ard.2026.01.023.","DOI":"10.1016\/j.ard.2026.01.023"},{"key":"10.1016\/j.ard.2026.03.020_bib109","doi-asserted-by":"crossref","unstructured":"Laskou F., Konzett V., Smolen J.S., Edwards C.J., Aletaha D., van der Heijde D., et al., Safety of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2026 Apr 7:S0003-4967(26)00143-3. https:\/\/doi.org\/10.1016\/j.ard.2026.02.024.","DOI":"10.1016\/j.ard.2026.02.024"},{"key":"10.1016\/j.ard.2026.03.020_bib0017","series-title":"Standard Operating Procedures for Task Forces [Internet]","year":"2024"},{"issue":"9","key":"10.1016\/j.ard.2026.03.020_bib0018","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"74","author":"Page","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.ard.2026.03.020_bib0019","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.ard.2026.03.020_bib0020","series-title":"Evidence-based medicine. How to practice and teach EBM","author":"Sackett","year":"2000"},{"key":"10.1016\/j.ard.2026.03.020_bib0021","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ard.2026.03.020_bib0022","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ard.2026.03.020_bib0023","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/mr\/roac103","article-title":"Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.ard.2026.03.020_bib0024","article-title":"Comparison of two dosing schedules for oral methotrexate (split-dose versus single-dose) once weekly in patients with active rheumatoid arthritis: a multicenter, open label, parallel group, randomized controlled trial (SMART Study) [abstract]","volume":"75","author":"Prasad","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2026.03.020_bib0025","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15319","article-title":"Efficacy and safety of methotrexate plus hydroxychloroquine combination therapy vs. methotrexate monotherapy in the treatment of rheumatoid arthritis: A randomized controlled clinical trial","volume":"27","author":"Ma","year":"2024","journal-title":"Int J Rheum Dis"},{"issue":"14","key":"10.1016\/j.ard.2026.03.020_bib0026","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1097\/CM9.0000000000003200","article-title":"The SMILE study: study of long-term methotrexate and iguratimod combination therapy in early rheumatoid arthritis","volume":"138","author":"Du","year":"2024","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"10.1016\/j.ard.2026.03.020_bib0027","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/rheumatology\/keab699","article-title":"SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study","volume":"61","author":"Li","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"20","key":"10.1016\/j.ard.2026.03.020_bib0028","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","article-title":"A Phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ard.2026.03.020_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003317","article-title":"The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis","volume":"9","author":"Kivitz","year":"2023","journal-title":"RMD Open"},{"issue":"suppl 9","key":"10.1016\/j.ard.2026.03.020_bib0030","article-title":"Efficacy, safety, pharmacokinetics of anti-CD40 antibody abiprubart in patients with rheumatoid arthritis: a phase 2, randomized, placebo-controlled 12-week-treatment proof-of-concept study [abstract]","volume":"76","author":"Jenkins","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.03.020_bib0031","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/annrheumdis-2024-eular.1536","article-title":"OP0036\u2005Efficacy, safety, and pharmacokinetics of anti-CD40 antibody abiprubart (KPL-404) in patients with rheumatoid arthritis: a phase 2, randomized, placebo-controlled 12-week-treatment proof-of-concept study","volume":"83","author":"Jenkins","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2026.03.020_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004278","article-title":"Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study","volume":"10","author":"Taylor","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2026.03.020_bib0033","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41392-022-00887-2","article-title":"Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.ard.2026.03.020_bib0034","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard-2023-224482","article-title":"Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)","volume":"82","author":"Fleischmann","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ard.2026.03.020_bib0035","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/ard-2023-224449","article-title":"Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)","volume":"82","author":"Taylor","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2026.03.020_bib0036","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40744-022-00519-9","article-title":"Bingham CO 3rd, et al. Sustained remission and outcomes with abatacept plus methotrexate following stepwise dose de-escalation in patients with early rheumatoid arthritis","volume":"10","author":"Emery","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"11","key":"10.1016\/j.ard.2026.03.020_bib0037","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/art.42273","article-title":"Phase II\/III Results of a trial of anti-tumor necrosis factor multivalent NANOBODY compound ozoralizumab in patients with rheumatoid arthritis","volume":"74","author":"Takeuchi","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.03.020_bib0038","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13075-022-02957-w","volume":"24","author":"Iwamoto","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.ard.2026.03.020_bib0039","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1136\/annrheumdis-2022-222228","article-title":"Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and\/or anti-TNFalpha therapy: a placebo-controlled phase II study","volume":"81","author":"Daien","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2026.03.020_bib0040","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S2665-9913(22)00092-3","article-title":"Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial","volume":"4","author":"Fleischmann","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2026.03.020_bib0041","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/ard-2022-223759","article-title":"Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial","volume":"82","author":"Takeuchi","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2026.03.020_bib0042","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/S2665-9913(23)00089-9","article-title":"Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study","volume":"5","author":"Conaghan","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.ard.2026.03.020_bib0043","article-title":"Efficacy and safety of the biased melanocortin receptor agonist AP1189\/resomelagon in combination with methotrexate in DMARD-na\u00efve rheumatoid arthritis patients: the EXPAND Trial [abstract]","volume":"76","author":"Bihlet","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.ard.2026.03.020_bib0044","article-title":"The BEGIN Study: a double-blind, multi-center, two-part, randomized, placebo-controlled study of the safety, tolerability, and efficacy of 4 weeks of treatment with AP1189 in early rheumatoid arthritis (RA) patients with active joint disease [abstract]","volume":"74","author":"Jonassen","year":"2022","journal-title":"Arthritis Rheumatology"},{"key":"10.1016\/j.ard.2026.03.020_bib0045","article-title":"Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study","volume":"42","author":"Yang","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"issue":"2","key":"10.1016\/j.ard.2026.03.020_bib0046","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/ard-2024-226385","article-title":"Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial","volume":"84","author":"Liu","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2026.03.020_bib0047","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/1756-185X.14801","article-title":"Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: an open-label randomized controlled trial","volume":"26","author":"Khan","year":"2023","journal-title":"Int J Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2026.03.020_bib0048","first-page":"1441","article-title":"AB0493 The efficacy and safety of tofacitinib in the treatment of DMARDs naive rheumatoid arthritis patients (eastern study)","volume":"82","author":"Zhao","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2026.03.020_bib0049","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/rheumatology\/keac582","article-title":"Favourable effect of a 'second hit' after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial","volume":"62","author":"Hartman","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.ard.2026.03.020_bib0050","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004535","article-title":"Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial","volume":"10","author":"Bertrand","year":"2024","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.ard.2026.03.020_bib0051","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard-2023-224116","article-title":"Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial","volume":"82","author":"Ostergaard","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"suppl 9","key":"10.1016\/j.ard.2026.03.020_bib0052","volume":"76","author":"Weinblatt","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.03.020_bib0053","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2024-eular.1541","volume":"83","author":"Maldonado","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2026.03.020_bib0054","first-page":"200","article-title":"LB0001\u2005Head-to-head comparison of TLL-018 and tofacitinib in patients with active rheumatoid arthritis: interim results from a phase IIa study","volume":"82","author":"Zeng","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"suppl 9","key":"10.1016\/j.ard.2026.03.020_bib0055","article-title":"Head-to-head comparison of TLL-018 and tofacitinib in patients with active rheumatoid arthritis: final results from a phase IIa study [abstract]","volume":"75","author":"Zeng","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.03.020_bib0056","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2024-eular.5266","article-title":"POS0017 successful therapeutic drug monitoring based adalimumab dose reduction in rheumatoid arthritis patients with low disease activity (ADDORA-LOW): a single-blind, non-inferiority, randomized clinical trial","volume":"83","author":"Atiqi","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.03.020_bib0057","first-page":"76","article-title":"Adalimumab dose reduction using therapeutic drug monitoring to manage low disease activity in rheumatoid arthritis: a single-blind, non-inferiority, randomized clinical trial [abstract]","author":"Atiqi","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.03.020_bib0058","first-page":"76","article-title":"Using adalimumab serum concentration to choose a subsequent DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): results of a blinded randomized test treatment trial [abstract]","author":"Wientjes","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2026.03.020_bib0059","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/art.42245","article-title":"The Efficacy of short-term bridging strategies with high- and low-dose prednisolone on radiographic and clinical outcomes in active early rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial","volume":"74","author":"Krause","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2026.03.020_bib0060","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.42415","volume":"75","author":"Buttgereit","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.ard.2026.03.020_bib0061","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1111\/cts.13624","article-title":"AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa, randomized, double-blind, efficacy, and safety study","volume":"16","author":"van Laar","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"4","key":"10.1016\/j.ard.2026.03.020_bib0062","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/S2665-9913(23)00070-X","article-title":"Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial","volume":"5","author":"Tamai","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"18","key":"10.1016\/j.ard.2026.03.020_bib0063","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1097\/CM9.0000000000002336","article-title":"Efficacy, safety, and cost-effectiveness of triple therapy in preventing relapse in rheumatoid arthritis: a randomized controlled trial (ESCoRT study)","volume":"135","author":"Zhao","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"11","key":"10.1016\/j.ard.2026.03.020_bib0064","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/ard-2023-224476","article-title":"Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial","volume":"82","author":"Lillegraven","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2026.03.020_bib0065","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/art.42752","article-title":"Towards the lowest efficacious dose: results from a multicenter noninferiority randomized open-label controlled trial assessing tocilizumab or abatacept injection spacing in rheumatoid arthritis in remission","volume":"76","author":"Kedra","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2026.03.020_bib0066","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/CM9.0000000000002561","article-title":"Continuation, reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter, open-label, randomized controlled trial","volume":"136","author":"Wang","year":"2023","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"10.1016\/j.ard.2026.03.020_bib0067","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003029","article-title":"Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study","volume":"9","author":"Kubo","year":"2023","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.ard.2026.03.020_bib0068","first-page":"316","article-title":"Baricitinib dose reduction in patients with rheumatoid arthritis achieving sustained disease control: final results from the RA-BEYOND study","volume":"52","author":"Edwards","year":"2025","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2026.03.020_bib0069","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1136\/ard-2023-223977","article-title":"Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial","volume":"82","author":"Almayali","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.03.020_bib0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/ard-2024-226620","article-title":"Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial","volume":"84","author":"Ruyssen-Witrand","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"30","key":"10.1016\/j.ard.2026.03.020_bib0071","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000039060","article-title":"Efficacy, safety and immunogenicity of the biosimilar etanercept compared to the reference formulation original etanercept in patients with rheumatoid arthritis: an open-label, randomized, comparative, multicenter study","volume":"103","author":"Pekhenko","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.ard.2026.03.020_bib0072","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40744-023-00544-2","article-title":"Efficacy and safety of CMAB008 compared with innovator infliximab in patients with moderate-to-severe rheumatoid arthritis receiving concomitant methotrexate: a randomized, double-blind, multi-center, phase III non-inferiority study","volume":"10","author":"Ye","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"1","key":"10.1016\/j.ard.2026.03.020_bib0073","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40744-021-00396-8","article-title":"Fine comparison of the efficacy and safety between GB242 and infliximab in patients with rheumatoid arthritis: a phase III study","volume":"9","author":"Liu","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2026.03.020_bib0074","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1136\/annrheumdis-2022-eular.1677","article-title":"AB0339\u2005efficacy, pharmacokinetics and safety between CT-P13 and China-approved infliximab: 54 week result from a phase III randomized controlled trial in Chinese patients with active rheumatoid arthritis","volume":"81","author":"Kay","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2026.03.020_bib0075","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/rheumatology\/keab460","article-title":"Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg\/ml): 52-week randomized, double-blind study in rheumatoid arthritis","volume":"61","author":"Furst","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.ard.2026.03.020_bib0076","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1016\/S2665-9913(23)00161-3","article-title":"Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study","volume":"5","author":"Fleischmann","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2026.03.020_bib0077","first-page":"76","article-title":"Assessment of comparative efficacy between candidate biosimilar AVT05 and reference golimumab [abstract]","author":"Luque","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.03.020_bib0078","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13075-022-02821-x","article-title":"Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study","volume":"24","author":"Zeng","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.ard.2026.03.020_bib0079","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004514","article-title":"Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47","volume":"10","author":"Smolen","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2026.03.020_bib0080","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003596","article-title":"Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study","volume":"10","author":"Zubrzycka-Sienkiewicz","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2026.03.020_bib0081","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2665-9913(23)00237-0","volume":"6","author":"Leng","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.03.020_bib0082","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13075-024-03375-w","volume":"26","author":"Leng","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.ard.2026.03.020_bib0083","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.42075","article-title":"Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial","volume":"74","author":"Matteson","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2026.03.020_bib0084","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-023-06623-7","article-title":"Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial","volume":"42","author":"Matteson","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2026.03.020_bib0085","first-page":"4105","article-title":"A randomized, double-blinded, placebo-controlled, phase 2 study of safety, tolerability and efficacy of pirfenidone in patients with rheumatoid arthritis interstitial lung disease","volume":"73","author":"Solomon","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.03.020_bib0086","volume":"74","author":"Deane","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2026.03.020_bib0087","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/ard.2008.105767","article-title":"Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial","volume":"69","author":"Bos","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.03.020_bib0088","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001591","article-title":"Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial","volume":"7","author":"van Boheemen","year":"2021","journal-title":"RMD Open"},{"issue":"10348","key":"10.1016\/j.ard.2026.03.020_bib0089","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(22)01193-X","article-title":"Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial","volume":"400","author":"Krijbolder","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ard.2026.03.020_bib0090","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","article-title":"Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study","volume":"78","author":"Gerlag","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10429","key":"10.1016\/j.ard.2026.03.020_bib0091","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(23)02650-8","article-title":"Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial","volume":"403","author":"Rech","year":"2024","journal-title":"Lancet"},{"issue":"10429","key":"10.1016\/j.ard.2026.03.020_bib0092","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","article-title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial","volume":"403","author":"Cope","year":"2024","journal-title":"Lancet"},{"issue":"suppl 9","key":"10.1016\/j.ard.2026.03.020_bib0093","article-title":"A phase 2b dose-ranging study of peresolimab for adults with RA [abstract]","volume":"77","author":"Tuttle","year":"2025","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ard.2026.03.020_bib0094","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/art.20982","volume":"52","author":"Smolen","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.ard.2026.03.020_bib0095","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1002\/art.22143","article-title":"Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes","volume":"54","author":"Landewe","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2026.03.020_bib0096","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/annrheumdis-2012-201970","article-title":"Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients","volume":"72","author":"Aletaha","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2026.03.020_bib0097","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2011-200395","article-title":"Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction","volume":"71","author":"Smolen","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2026.03.020_bib0098","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","article-title":"Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ard.2026.03.020_bib0099","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2026.03.020_bib0100","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2026.03.020_bib0101","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"10271","key":"10.1016\/j.ard.2026.03.020_bib0102","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ard.2026.03.020_bib0103","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/annrheumdis-2021-221957","article-title":"Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial","volume":"81","author":"Boers","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2026.03.020_bib0104","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"18","key":"10.1016\/j.ard.2026.03.020_bib0105","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2026.03.020_bib0106","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ard.2025.05.027","article-title":"OP0004\u2005abatacept in individuals at risk of developing rheumatoid arthritis: results from the arthritis prevention in the pre-clinical phase of RA with abatacept long term outcomes (ALTO) study","volume":"84","author":"Cope","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.03.020_bib0107","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ard.2025.05.327","article-title":"OP0325 long-term prevention of RA in high-risk individuals after a 6-month placebo-controlled intervention with abatacept\u2014the ARIAA trial","volume":"84","author":"Tascilar","year":"2025","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726002062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726002062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T20:30:36Z","timestamp":1780864236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726002062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":109,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0003496726002062"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.03.020","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}